• Advertise
  • Contact Us
  • Write For Us
  • Our Team
Extraction Magazine
No Result
View All Result
  • Botanical Extraction
    • Cannabinoids
    • Psychedelics
    • Nutraceutical
    • Product Refinement
  • Industry News
    • Business
    • Sustainability
    • Safety & Compliance
    • Partners
  • Extraction Technology
    • Equipment
    • Methods
    • Solvents
    • DIY Extraction
    • Analytical Techniques
  • Medical Research
  • Glossary
  • Business Directory
  • Botanical Extraction
    • Cannabinoids
    • Psychedelics
    • Nutraceutical
    • Product Refinement
  • Industry News
    • Business
    • Sustainability
    • Safety & Compliance
    • Partners
  • Extraction Technology
    • Equipment
    • Methods
    • Solvents
    • DIY Extraction
    • Analytical Techniques
  • Medical Research
  • Glossary
  • Business Directory
No Result
View All Result
Extraction Magazine
No Result
View All Result
Home Industry News Partners

In Pursuit of a “Cleaner” Cannabidiol

Loren DeVito, PhD by Loren DeVito, PhD
February 14, 2019
in Partners
In Pursuit of a “Cleaner” Cannabidiol

Kannalife’s Douglas Brenneman, PhD, discusses his team’s discovery of a novel compound that may overcome the pharmacological shortcomings of CBD

Cannabidiol (CBD), the current “darling” of the cannabinoid family, has a big problem – its multitude of mechanisms of action. CBD affects several systems in the body by binding to a host of receptors beyond cannabinoid (CB) 1 and 2. In fact, CBD interacts with GPR55, TRPV1 and 5-HT1A receptors, among others, many of which are currently under study. These widespread mechanisms of action explain how CBD can be effective for pain, inflammation, anxiety, and even psychosis. [1]

READ ALSO

Hydrocarbons as a Critical Part of the Process — The Solvent Industry in 2024

The Budtender’s Guide: A Reference Manual for Dispensary Professionals and Cannabis Consumers

This comprehensive range of effects may seem beneficial to patients, as taking just one dose of CBD could potentially ameliorate a host of symptoms. But, for researchers and drug companies trying to advance the development of a CBD formulation to be used by one specific patient population for one condition, this poses a significant barrier. Luckily, scientists at Kannalife, Inc., a phyto-medical company, are making strides to overcome this challenge.

Kannalife is developing cannabinoid-based therapeutics designed to treat and prevent neurological conditions caused by oxidative and neurotoxic stress, and have patented a CBD-derived neuroprotective agent, KLS-13019, to treat hepatic encephalopathy. We spoke to Douglas Brenneman, PhD, co-inventor of Kannalife’s recent patent, whose team discovered KLS-13019.

Dr. Brenneman is a neuropharmacologist who never imagined that his research would take him into the cannabis sector. His entire career has focused on developmental neurobiology and how to protect the nervous system from damage, what he calls a “very formidable task.” Brenneman works with primary neural cultures, simulating drug delivery to cells in the brain, to better understand how different drugs affect the physiological and molecular processing within and between cells.

While Brenneman spent many years working at the National Institute of Health, he also gained invaluable experience in industry science as a team leader at Johnson & Johnson. Thus, his integrated academic and industry training prepared him for a transition to entrepreneurial CBD science when he joined Kannalife.

Sara Jane Ward, PhD, Assistant Professor of Pharmacology at Temple University, a colleague of Brenneman’s, first introduced him to CBD science. Dr. Ward is particularly interested in the effect of cannabinoids on neuropathic pain. The two began collaborating and still work together today – but it took some convincing to first get Brenneman on board. Brenneman described his initial interactions with CBD as follows: “It worked…[but]…I was very unimpressed with its potency.”

As a pharmacologist who has spent considerable time trying to develop “druggable” compounds, Brenneman was frustrated at the high doses of CBD required to produce an effect. And he was not happy that CBD has a “bewildering number of pharmacological actions.”

To move a compound from the discovery phase into clinical trials, it must have a “clean” and specific mechanism of action, a low-to-mid-range dose, and an acceptable safety profile. If pharmacologists are not certain of these properties, it is likely that the compound will fail clinical trials and thus be “killed” (removed from the pipeline) so that it doesn’t advance into human testing.

“Big Pharma would never move [CBD] forward because it’s really a dirty…compound…

and that’s where Kannalife came in,” said Brenneman. “They wanted…our team to address the shortcomings of CBD, and to try to modify its structure in hopes of getting something a little cleaner, a little more directed.”

And, so, with a team of experts in tow, Brenneman began to work toward a “cleaner” CBD that could be used to treat hepatic encephalopathy, a rare disorder that causes a range of neurological conditions that develops in some people with liver disease. This search led to the discovery of KLS-13019, a novel small molecule created by adding heteratoms on the pentyl groups of CBD. This chemical structure change aimed to increase solubility. [2]

Careful analysis of this compound revealed that it is 50-fold more potent and >400-fold safer than CBD. In addition, KLS-13019 has improved oral bioavailability, the amount of active drug that enters the blood system and can therefore take effect. [2] In a more recently published study, Brenneman and his team found that, compared to CBD, KLS-13019 is 31-fold more potent in preventing damage to neurons caused by toxins, and that KLS-13019 is safer than CBD (5-fold less toxic). [3] Taken together, these studies indicate that KLS-13019 may be an effective alternate to CBD.

These results may be slightly confusing for many, as CBD is marketed as a very safe compound. Not always, said Brenneman.

Across his many years of research, Brenneman has found that CBD, at certain concentrations, actually can cause neurotoxicity. This is certainly alarming to hear, especially since the FDA recently approved a CBD-based therapy, Epidiolex™, to treat severe forms of pediatric epilepsy. While clinical trials demonstrated that this product is both effective and safe, Brenneman is concerned with its long-term effects on cognition.

“We know that the [developing nervous system] has different vulnerabilities than the mature system,” said Brenneman. “Detailed studies [should be] done on learning and memory in children and in adults…the ‘all-clear’ [on CBD] is not there yet.”

It’s important to take his concerns into consideration when deciding to use CBD medicinally; however, the nervous system is quite complex and the effects of certain compounds on the entire body compared to individual cells are likely quite different.

Still, the science behind CBD certainly does not yet warrant dosing everyday food and drink with the compound without further evaluation of its long-term effects. But one thing is for certain – as the medical cannabis industry continues to expand, companies like Kannalife must continue pursuing research into cannabinoids as they would for any other potential medicine.

Creating cleaner compounds that take a more targeted effect on receptors and systems in the body will advanced cannabis science and move more potential drugs into clinical trial – and gain greater acceptance by following the traditional path toward drug development and approval.

References

  1. Campos, A.C., Moreira, F.A., Gomes, F.V., Del Bel, E.A., Guimarães, F.S., “Multiple Mechanisms Involved in the Large-spectrum Therapeutic Potential of Cannabidiol in Psychiatric Disorders”, Philos Trans R SocLond B BiolSci, 2012, Volume 367, pg. 3364-3378. (impact factor: 5.57; cited by: 198)
  1. Kinney, W.A., McDonnell, M.E., Zhong, H.M., et al., “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability”, ACS Med Chem Lett, 2016, Volume 7, pg. 424-428. (impact factor: 3.794; cited by: 6)
  1. Brenneman, D.E., Petkanas, D., Kinney, W.A., “Pharmacological Comparisons Between Cannabidiol and KLS-13019”, J MolNeurosci, 2018, Volume 66, pg. 121-134. (impact factor: 2.891; cited by: N/A)

Related Posts

Hydrocarbons as a Critical Part of the Process — The Solvent Industry in 2024
Extraction Technology

Hydrocarbons as a Critical Part of the Process — The Solvent Industry in 2024

March 1, 2024
The Budtender's Guide: A Reference Manual for Dispensary Professionals and Cannabis Consumers
Industry News

The Budtender’s Guide: A Reference Manual for Dispensary Professionals and Cannabis Consumers

May 18, 2023
Fast-Acting Nano-Based Products Are Boring. They Are Too High in THC % and Too Weak in the Experience They Provide.  It Is Time to Reveal the Full Potential with Help from Expert Extractors.
Extraction Technology

Fast-Acting Nano-Based Products Are Boring. They Are Too High in THC % and Too Weak in the Experience They Provide. It Is Time to Reveal the Full Potential with Help from Expert Extractors.

September 2, 2022
The unknowns of Delta 8 THC
Partners

The unknowns of Delta 8 THC

July 20, 2022
Not For Human Consumption!
Partners

Not For Human Consumption!

July 18, 2022
Company Spotlight: ENTEXS, the Future of Extraction and THC Remediation Technology
Partners

Company Spotlight: ENTEXS, the Future of Extraction and THC Remediation Technology

May 17, 2022
Next Post
Betting On California: CalivaRaises $75M To Invest In Largest Global Cannabis Market

Betting On California: CalivaRaises $75M To Invest In Largest Global Cannabis Market

LATEST ARTICLES

Green Extraction Techniques

Green Extraction Techniques and Smart Solvents for Bioactive Recovery

January 10, 2025
Wide angle view at two workers wearing protective suits while inspecting production at modern chemical plant, copy space

Collaborative Approaches in Botanical Extraction: Bridging Science and Industry

January 7, 2025
Areca Catechu

Inside the Betel Nut High: Exploring the Mind-Bending Effects of Areca Catechu

January 1, 2025
The Art of Extraction: Unlocking Nature’s Fragile Secrets

The Art of Extraction: Unlocking Nature’s Fragile Secrets

December 27, 2024

Subscribe Now

Subscribe to our newsletter now to receive quick updates from us



    Background
    About

    Extraction Magazine is the trusted provider of botanical extraction news, ever-changing politics, cool gadgets and technologies, and methods for producing safe, ethical, and compliant formulations.

    Advertisers
    Navigation
    • Botanical Extraction
    • Industry News
    • Extraction Technology
    • Medical Research
    • Glossary
    • Business Directory
    Recent Posts
    • Green Extraction Techniques and Smart Solvents for Bioactive Recovery
    • Collaborative Approaches in Botanical Extraction: Bridging Science and Industry
    • Inside the Betel Nut High: Exploring the Mind-Bending Effects of Areca Catechu
    • The Art of Extraction: Unlocking Nature’s Fragile Secrets
    Subscribe to our Newsletter
    loader

    Sitemap

    © 2025 Extraction Magazine is the trusted provider of botanical extraction news and the leading media in the ever-changing extraction industry.

    No Result
    View All Result
    • Industry News
    • Botanical Extraction
    • Medical Research
    • Medical Research
    • Glossary
    • Our Team
    • Write For Us

    © 2023 Extraction Magazine is the trusted provider of botanical extraction news and the leading media in the ever-changing extraction industry.